ABSTRACT
INTRODUCTION
 18 
F-fluorodeoxyglucose (
18 F-FDG) positron emission tomography (PET) imaging has emerged as an important clinical tool for cancer detection, staging and monitoring of response to therapy, 18 F-FDG PET is routinely used in the clinical management of several cancer types [1] . 18 F-FDG, a glucose analog, was synthesized approximate 4 decades ago. In 1968, Pacak et al were the first to describe the synthesis of "cold" FDG [2] . In the 1970s, Ido and Wolf reported the synthesis of 18 F-FDG [3] . In 1976, researchers at the University of Pennsylvania obtained the first 18 F-FDG brain images in two health volunteers [4] .
In 1861, French chemist and microbiologist Louis Pasteur found the increase in cell mass of yeast under anaerobic condition was smaller than aerobically, but the rate of sugar breakdown in yeast was higher in anerobic condition than the presence of oxygen, referred as Pasteur effect [5] [6] [7] . Pasteur effect can be easily explained when the oxygen concentration is low, the energy production efficiency is low. If the oxygen concentration grows, yeast increases the efficiency to 32 moles of adenosine triphosphate (ATP) per mole of glucose. Although Pasteur effect seems more frequently apply in microbiology, it oncology application is less popular. In fact,
18
F-FDG accumulation is found significant higher in hypoxic cancer cells than in well oxygenated ones, which may be explained by Pasteur effect [8] [9] [10] [11] [12] .
In early 1920s, German biologist Otto Warburg reported that, in the presence of ample oxygen, cancer cells prefer to metabolize glucose by "aerobic glycolysis", so called Warburg effect [13] . The increase in glucose demand has been considered as one of the fundamental Review www.impactjournals.com/oncotarget features of cancer [13, 14] , which has also become the fundamental of 18 F-FDG PET in oncology application. However, some malignancies had low 18 F-FDG PET findings [15] , which is unexplainable by Warburg effect. Therefore, better understanding of 18 F-FDG uptake mechanism is important for better cancer practice.
In 2009, Lisanti and colleagues proposed "the reverse Warburg effect" hypothesis in human breast cancers. They claimed the Warburg effect actually took place in tumor associated fibroblasts, and not in cancer cells [16] [17] [18] [19] [20] . Zhang et al have examined the hypothesis in cancer cells growing in nude mice with 18 F-FDG PET study [8] .
Understanding 18 F-FDG uptake mechanism in cancer is essential for better understanding cancer biology. Cancer is not a collection of pure cancer cells, which is composed by multiple complex components and is considered as an "organ", the so called systems biology. In addition, cancer also follows "Darwin Dynamics" for survival, in other words, the fraction of each component or molecular level events of cancer may change dramatically to adapt the change of microenvironment [21] .
In this article, we revisited the 18 F-FDG uptake mechanisms and its oncology applications. We propose "systems molecular imaging" initiative for better understanding systems biology of cancer, and we discussed the role of 18 F-FDG PET in systems molecular imaging. [8] [9] [10] [11] [12] .
RESULTS AND
Spatial co-localization was found between high 18 F-FDG uptake and tumor hypoxia, and such regions also had low blood perfusion. On the other hand, non-hypoxic regions displayed low 18 F-FDG uptake. In addition, both stroma and necrotic zones were also associated with lower 18 F-FDG activity [11] . Our clinical data support the preclinical findings, high glucose metabolism region at 60-min 18 F-FDG PET of lung cancer associated with low blood perfusion detected by early phase [29] . Although cellular proliferation and hypoxia are generally exclusive, the presence of tumor hypoxia is because of faster cancer cells proliferation than angiogenesis. It has been recently demonstrated that proliferating cancer cells in oxic cancer zones have lower 18 F-FDG uptake comparing to less proliferating cancer cells locating in hypoxic zones of a cancer [8] [9] [10] [11] [12] , it is not surprise necrosis is associated with low
18
F-FDG accumulation [11] . In a malignant cancerous lesion, areas of low 18 F-FDG accumulation either represent well proliferating cancer cells or necrosis or non-cancerous stroma. In patient, high 18 F-FDG accumulation does not mean the region with proliferating cancer cells, but indicates cancer cells are with low proliferating rate, lack of 18 F-FDG does not necessarily mean absence of viable cancer cells. Accordingly, great attention should be paid to manage cancer therapy with 18 F-FDG PET.
F-FDG uptake and glucose transporters
Glucose transportor-1 (GLUT-1) has been considered as an important factor for glucose metabolism, which over-expresses in hypoxic cancer cells. Clavo et al [22] found increased 3 H-FDG uptake in carcinoma cell lines and attributed it partly due to increased membrane expression of GLUT-1. In contrast, Burgman et al [23] described hypoxia increased 3 H-FDG uptake in MCF7 breast carcinoma cells even without any detectable increase in GLUT-1 expression, but an increase in glucose transporter activity. We found that metastatic peritoneal colorectal cancer cells manifest significant changes in 18 F-FDG uptake when animals were switched breathing from air to carbogen even in the absence of apparent changes in GLUT-1 expression [12] . Although it is possible that alterations in hexokinase activity may be involved, Waki et al found no correlation between hexokinase activity and 3 H-2-deoxyglucose uptake for different tumor cell lines [29] . High GLUT-1 expression by itself, therefore, is insufficient to ensure high 18 F-FDG uptake [12] . Immunohistochemical assay of GLUT-1 expression has been used for evaluation of hypoxia fraction in patients, considering GLUT-1 as an "historic" hypoxia marker [12, 30] , 18 F-FDG PET may be more accurate than histological assay of GLUT-1 to estimate hypoxia fraction of malignancies in patients.
Effect of high concentration oxygen breathing on 18 F-FDG uptake
Li et al addressed the effect of carbogen breathing on 18 F-FDG uptake in a dual-hypoxia markers studies, carbogen breathing significantly decreased hypoxia status in animal models of cancer [12, [31] [32] [33] [34] [35] . Carbogenbreathing producing rapid decrease in tumor 18 F-FDG uptake raises concerns, in particular, interpretation difficulties may arise when the changes in 18 F-FDG uptake are used to monitor the tumor's response to therapy; hypoxic status changes in the tumor induced by the therapy may be challenged when the patient becomes oxygen dependent. A pilot study confirmed that patients' oxygen breathing during 18 F-FDG uptake phase may blunt the degree of tumor 18 F-FDG uptake measured by SUV max [36] .
F-FDG uptake in metastases
We recently reported the use of correlative imaging methodologies to examine the uptake of 18 F-FDG in disseminated peritoneal metastases growing in mice.
Microscopic examination of peritoneal tumor sections indicated a characteristic relationship between the pattern of hypoxia and tumor size. In general, the smallest tumor deposits ( < ~1 mm diameter) showed intense hypoxic and relatively poorly perfused. Larger tumors (~1-4 mm diameter) appeared relatively well perfused with higher proliferation rate and containing less hypoxia [9, 11, 12, 31, [37] [38] [39] . There was spatial co-localization between high levels of tumor 18 F-FDG uptake, pimonidazole binding and GLUT-1 expression. Such regions tended to correspond to low levels of cellular proliferation and blood perfusion. In particular, the smallest hypoxic tumor deposits had highest 18 F-FDG uptake. Less hypoxic larger tumors displayed relatively low 18 F-FDG uptake [38] . Therefore,
18
F-FDG uptake was significantly high in hypoxic microscopic tumors, and in only hypoxic regions of macroscopic tumors.
On microscopic examination, HT29 ascites tumors appeared similar to small avascular HT29 peritoneal tumors of < 1 mm in diameter. Ascites tumors are severely hypoxic [9, 11, 12, 31] which had high 18 F-FDG uptake [12] . Therefore, in clinical setting, a PET/CT finding of diffusely increased
F-FDG activity in ascites fluid may be an indicative of malignancies.
Revisit 18 F-FDG PET/CT application in oncology
During the past decades, the wide use of F-FDG PET for cancer detection is because 95% of solid malignancies contain some degree of hypoxia [40] [41] [42] . Better understanding of the intratumoral 18 F-FDG distributions will enable us to overcome most of the challenges that we face in our daily diagnostic and therapeutic clinical dilemmas in oncology, as well as systems molecular imaging application [43] . www.impactjournals.com/oncotarget
MATERIALS AND METHODS
In this article, part of the data presented here was obtained from our laboratories and PET center. The animal protocols were approved by the Institutional Animal Care and Use Committees of Harbin Medical University and University of Louisville; The Human PET study the use of the human data was approved by institutional review board of Harbin Medical University, in all patients, a written content was obtained, and good clinical practice was followed. We systemic review up-to-date literature with respect to 18 F-FDG, cancer, hypoxia, Warburg effect, and glucose metabolism in pubmed database.
Cancer cell lines and nude mice
The human cancer H460, HT29 and A549 cells were used in experiments to generate xenografts in nude mice. All experiments were performed using 7 week old female nude mice. Animals were housed five per cage and kept in the institutional small animal facility at a constant temperature and humidity.
Preparation of 18 F-FDG, markers of hypoxia and perfusion
18 F-fluoride was produced by an in-house cyclotron.
18
F-FDG was prepared with an automated modularlab system (Eckert & Ziegler; Berlin, Germany). Radiochemical yields by thin layer chromatography were approximately 75% and radiochemical purity was greater than 99%.
In animal studies, the hypoxia marker, pimonidazole hydrochloride (Hypoxyprobe Inc) was dissolved in physiological saline at a concentration of 20 mg/ml. The blood perfusion marker, Hoechst 33342 (Sigma-Aldrich) was dissolved in physiological saline at a concentration of 5 mg/ml. Fresh drug solutions were prepared on the day of each experiment. All injections were given via tail veins. Pimonidazole was given as 2 mg in 0.1 ml PBS; Hoechst 33342 as 0.5 mg in 0.1 ml PBS; 7.4 MBq of 18 F-FDG was administered either singly (for PET imaging) or as a coinjection with pimonidazole. Hoechst 33342 was always administered 1minute before sacrifice. For patient studies, only 
Preparation of frozen tumor sections
Immediately after animal sacrifice, xenografts were removed, frozen and embedded in optimal cutting temperature medium (Sakura Finetek). Five contiguous 7-μm-thick tissue sections were cut using a Microm HM500 cryostat microtome (Microm International GmbH).
Digital autoradiography
Autoradiograms were obtained by placing the tumor sections in a film cassette against an imaging plate as described previously [8] . The plate read by a Cyclone Plus imaging system (PerkinElmer, Inc). Regions of interest (100 × 100µm) were drawn over hypoxic cancer cells regions, oxic cancer cells regions and stroma in digital autoradiography referring immunohistochemical and hematoxylin and eosin stain images obtained from same or an adjacent section for digital autoradiography.
Immunohistochemical staining of tumor sections
Pimonidazole and Hoechst 33342 images were obtained after completion of digital autoradiography exposures if applied. The same tumor sections were used for all images in order to minimize issues associated with section registration. Slides were air-dried, fixed in cold acetone (4 o C) for 20 min, and incubated with SuperBlock (Pierce Biotechnology) at room temperature for 30 min. All antibodies were also applied in SuperBlock. Sections were then incubated with FITC conjugated antipimonidazole monoclonal antibody (Hypoxyprobe Inc) for one hour at room temperature.
PET imaging
All animals were imaged in a prone position using Siemens Inveon Micro-PET (Siemens Medical Solutions Knoxville, TN) system. All human imaging was obtained from a GE DISCOVERY 690 ELITE PET/CT scanner.
